Detalhe da pesquisa
1.
Support to early clinical decisions in drug development and personalised medicine with checkpoint inhibitors using dynamic biomarker-overall survival models.
Br J Cancer
; 129(9): 1383-1388, 2023 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-36765177
2.
Nonlinear multilevel joint model for individual lesion kinetics and survival to characterize intra-individual heterogeneity in patients with advanced cancer.
Biometrics
; 79(4): 3752-3763, 2023 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-37498050
3.
Modelling the association between biomarkers and clinical outcome: An introduction to nonlinear joint models.
Br J Clin Pharmacol
; 88(4): 1452-1463, 2022 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-34993985
4.
Confounding factors in exposure-response analyses and mitigation strategies for monoclonal antibodies in oncology.
Br J Clin Pharmacol
; 87(6): 2493-2501, 2021 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-33217012
5.
Bayesian inference using Hamiltonian Monte-Carlo algorithm for nonlinear joint modeling in the context of cancer immunotherapy.
Stat Med
; 39(30): 4853-4868, 2020 12 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-33032368
6.
Longitudinal analysis of organ-specific tumor lesion sizes in metastatic colorectal cancer patients receiving first line standard chemotherapy in combination with anti-angiogenic treatment.
J Pharmacokinet Pharmacodyn
; 47(6): 613-625, 2020 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-32865652
7.
A modeling and simulation-based assessment of the impact of confounding factors on the readout of a sildenafil survival trial in pulmonary arterial hypertension.
J Pharmacokinet Pharmacodyn
; 46(5): 499-509, 2019 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-31538282
8.
Modeling and simulation of maintenance treatment in first-line non-small cell lung cancer with external validation.
BMC Cancer
; 16: 473, 2016 07 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-27412292
9.
Letter to the editor: Model-based simulation to support the extended dosing regimens of atezolizumab.
Eur J Clin Pharmacol
; 77(7): 1065-1066, 2021 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-33415499
10.
Comparison of two-stage and joint TGI-OS modeling using data from six atezolizumab clinical studies in patients with metastatic non-small cell lung cancer.
CPT Pharmacometrics Syst Pharmacol
; 13(1): 68-78, 2024 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-37877248
11.
Tumor growth and overall survival modeling to support decision making in phase Ib/II trials: A comparison of the joint and two-stage approaches.
CPT Pharmacometrics Syst Pharmacol
; 13(6): 1017-1028, 2024 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-38629452
12.
External validation of a tumor growth inhibition-overall survival model in non-small-cell lung cancer based on atezolizumab studies using alectinib data.
Cancer Chemother Pharmacol
; 92(3): 205-210, 2023 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-37410154
13.
Assessing the Increased Variability in Individual Lesion Kinetics During Immunotherapy: Does It Exist, and Does It Matter?
JCO Precis Oncol
; 7: e2200368, 2023 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-36848611
14.
Multistate Pharmacometric Model to Define the Impact of Second-Line Immunotherapies on the Survival Outcome of the IMpower131 Study.
Clin Pharmacol Ther
; 113(4): 851-858, 2023 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-36606486
15.
Early Decision Making in a Randomized Phase II Trial of Atezolizumab in Biliary Tract Cancer Using a Tumor Growth Inhibition-Survival Modeling Framework.
Clin Pharmacol Ther
; 114(3): 644-651, 2023 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-37212707
16.
Tumor Dynamic Model-Based Decision Support for Phase Ib/II Combination Studies: A Retrospective Assessment Based on Resampling of the Phase III Study IMpower150.
Clin Cancer Res
; 29(6): 1047-1055, 2023 03 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-36595566
17.
The American Conference on Pharmacometrics 2017 (ACoP8).
J Pharmacokinet Pharmacodyn
; 44(Suppl 1): 1-2, 2017 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-28948580
18.
Tumor Growth Inhibition-Overall Survival (TGI-OS) Model for Subgroup Analysis Based on Post-Randomization Factors: Application for Anti-drug Antibody (ADA) Subgroup Analysis of Atezolizumab in the IMpower150 Study.
AAPS J
; 24(3): 58, 2022 04 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-35484442
19.
Extension of the Alternative Intravenous Dosing Regimens of Atezolizumab into Combination Settings through Modeling and Simulation.
J Clin Pharmacol
; 62(11): 1393-1402, 2022 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-35576521
20.
Evaluation of atezolizumab immunogenicity: Efficacy and safety (Part 2).
Clin Transl Sci
; 15(1): 141-157, 2022 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34582105